$CADL
Candel Therapeutics, Inc.

2023 Q4 Form 10-Q Financial Statement

#000095017023061566 Filed on November 09, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $0.00 $0.00
YoY Change -100.0% -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.060M $3.020M
YoY Change -3.16% -14.59%
% of Gross Profit
Research & Development $6.782M $5.845M
YoY Change 42.78% 8.72%
% of Gross Profit
Depreciation & Amortization $249.0K $200.0K
YoY Change 12.67% -2.44%
% of Gross Profit
Operating Expenses $10.12M $8.861M
YoY Change 24.42% -0.57%
Operating Profit -$8.861M
YoY Change -0.23%
Interest Expense -$258.0K $669.0K
YoY Change -214.16% -480.11%
% of Operating Profit
Other Income/Expense, Net -$519.0K $426.0K
YoY Change -118.59% 120.73%
Pretax Income -$11.10M -$8.440M
YoY Change 118.28% -2.85%
Income Tax
% Of Pretax Income
Net Earnings -$11.10M -$8.435M
YoY Change 118.28% -2.91%
Net Earnings / Revenue
Basic Earnings Per Share -$0.29
Diluted Earnings Per Share -$0.38 -$0.29
COMMON SHARES
Basic Shares Outstanding 28.92M 28.92M
Diluted Shares Outstanding 28.92M

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $35.41M $43.00M
YoY Change -49.45% -44.29%
Cash & Equivalents $35.40M $43.00M
Short-Term Investments
Other Short-Term Assets $1.384M $2.100M
YoY Change -26.66% 11.29%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $36.80M $45.10M
YoY Change -48.85% -42.96%
LONG-TERM ASSETS
Property, Plant & Equipment $3.206M $3.676M
YoY Change -27.53% -19.4%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $382.0K $400.0K
YoY Change 43.61% 50.38%
Total Long-Term Assets $4.404M $4.960M
YoY Change -23.36% -16.46%
TOTAL ASSETS
Total Short-Term Assets $36.80M $45.10M
Total Long-Term Assets $4.404M $4.960M
Total Assets $41.20M $50.06M
YoY Change -46.97% -41.11%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $422.0K $250.0K
YoY Change 11.05% -74.23%
Accrued Expenses $4.356M $3.429M
YoY Change -7.77% -22.86%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $8.893M $6.100M
YoY Change
Total Short-Term Liabilities $14.18M $10.33M
YoY Change 152.61% 75.09%
LONG-TERM LIABILITIES
Long-Term Debt $11.63M $14.34M
YoY Change -44.21% -30.89%
Other Long-Term Liabilities $1.889M $1.600M
YoY Change -46.21% -74.33%
Total Long-Term Liabilities $11.63M $14.34M
YoY Change -52.25% -46.86%
TOTAL LIABILITIES
Total Short-Term Liabilities $14.18M $10.33M
Total Long-Term Liabilities $11.63M $14.34M
Total Liabilities $28.46M $27.04M
YoY Change -5.07% -17.76%
SHAREHOLDERS EQUITY
Retained Earnings -$137.0M -$125.9M
YoY Change 38.24% 33.94%
Common Stock $150.2M $149.4M
YoY Change 2.02% 1.93%
Preferred Stock
YoY Change
Treasury Stock (at cost) $448.0K $448.0K
YoY Change 0.0% 0.0%
Treasury Stock Shares
Shareholders Equity $12.75M $23.02M
YoY Change
Total Liabilities & Shareholders Equity $41.20M $50.06M
YoY Change -46.97% -41.11%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$11.10M -$8.435M
YoY Change 118.28% -2.91%
Depreciation, Depletion And Amortization $249.0K $200.0K
YoY Change 12.67% -2.44%
Cash From Operating Activities -$7.422M -$8.810M
YoY Change 7.8% -6.12%
INVESTING ACTIVITIES
Capital Expenditures $47.00K $100.0K
YoY Change -82.97% -146.51%
Acquisitions
YoY Change
Other Investing Activities $20.00K $0.00
YoY Change
Cash From Investing Activities -$27.00K -$100.0K
YoY Change -90.22% -53.49%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -121.0K 0.000
YoY Change -436.11%
NET CHANGE
Cash From Operating Activities -7.422M -8.810M
Cash From Investing Activities -27.00K -100.0K
Cash From Financing Activities -121.0K 0.000
Net Change In Cash -7.570M -8.910M
YoY Change 6.25% -7.18%
FREE CASH FLOW
Cash From Operating Activities -$7.422M -$8.810M
Capital Expenditures $47.00K $100.0K
Free Cash Flow -$7.469M -$8.910M
YoY Change 4.3% -2.82%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001841387
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2023Q3 us-gaap Property Plant And Equipment Useful Life Description Of Term Extensible Enumeration
PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration
http://fasb.org/us-gaap/2023#LeaseholdImprovementsMember
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40629
dei Entity Registrant Name
EntityRegistrantName
CANDEL THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
52-2214851
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-342000
dei Entity Address Address Line1
EntityAddressAddressLine1
117 Kendrick St
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 450
dei Entity Address City Or Town
EntityAddressCityOrTown
Needham
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02494
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
916-5445
dei Security12b Title
Security12bTitle
Common Stock, par value $0.01 per share
dei Trading Symbol
TradingSymbol
CADL
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
28919810
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
42983000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
70058000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2118000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1887000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
45101000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
71945000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3676000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4424000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
879000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1056000
CY2023Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
266000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
266000
CY2023Q3 us-gaap Other Assets
OtherAssets
139000
CY2023Q3 us-gaap Assets
Assets
50061000
CY2022Q4 us-gaap Assets
Assets
77691000
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
250000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
380000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3429000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4723000
CY2023Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
6100000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
500000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
464000
CY2023Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
48000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
48000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
10327000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5615000
CY2023Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
108000
CY2022Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
144000
CY2023Q3 us-gaap Long Term Loans From Bank
LongTermLoansFromBank
14339000
CY2022Q4 us-gaap Long Term Loans From Bank
LongTermLoansFromBank
20202000
CY2023Q3 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
725000
CY2022Q4 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
648000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1107000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1486000
CY2023Q3 cadl Warrant Liability Noncurrent
WarrantLiabilityNoncurrent
433000
CY2022Q4 cadl Warrant Liability Noncurrent
WarrantLiabilityNoncurrent
1882000
CY2023Q3 us-gaap Liabilities
Liabilities
27039000
CY2022Q4 us-gaap Liabilities
Liabilities
29977000
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29042418
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29042418
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
28919810
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
28919810
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
290000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
290000
CY2023Q3 us-gaap Treasury Stock Value
TreasuryStockValue
448000
CY2022Q4 us-gaap Treasury Stock Value
TreasuryStockValue
448000
CY2023Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
149113000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
146961000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-125933000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-99089000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
23022000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
47714000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
50061000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
77691000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
31000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
94000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5845000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5376000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17248000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15815000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3016000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3536000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10825000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10900000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
8861000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
8912000
us-gaap Operating Expenses
OperatingExpenses
28073000
us-gaap Operating Expenses
OperatingExpenses
26715000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-8861000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-8881000
us-gaap Operating Income Loss
OperatingIncomeLoss
-28073000
us-gaap Operating Income Loss
OperatingIncomeLoss
-26621000
CY2023Q3 us-gaap Nonoperating Gains Losses
NonoperatingGainsLosses
12000
us-gaap Nonoperating Gains Losses
NonoperatingGainsLosses
36000
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
502000
CY2022Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
343000
us-gaap Investment Income Interest
InvestmentIncomeInterest
1666000
us-gaap Investment Income Interest
InvestmentIncomeInterest
414000
CY2023Q3 us-gaap Interest Expense
InterestExpense
669000
CY2022Q3 us-gaap Interest Expense
InterestExpense
519000
us-gaap Interest Expense
InterestExpense
1922000
us-gaap Interest Expense
InterestExpense
1130000
CY2023Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-581000
CY2022Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-369000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1449000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-13626000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
426000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
193000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1229000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
12910000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-8435000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-8688000
us-gaap Net Income Loss
NetIncomeLoss
-26844000
us-gaap Net Income Loss
NetIncomeLoss
-13711000
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.29
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.29
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.3
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.3
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.93
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.93
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.48
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.48
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28919810
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28919810
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28891909
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28891909
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28919810
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28919810
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28798284
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28798284
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
47714000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2278000
us-gaap Adjustments To Additional Paid In Capital Mark To Market
AdjustmentsToAdditionalPaidInCapitalMarkToMarket
-126000
us-gaap Net Income Loss
NetIncomeLoss
-26844000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
23022000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
30771000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
735000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Mark To Market
AdjustmentsToAdditionalPaidInCapitalMarkToMarket
-49000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-8435000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
23022000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
64137000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
476000
us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
448000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2309000
us-gaap Adjustments To Additional Paid In Capital Mark To Market
AdjustmentsToAdditionalPaidInCapitalMarkToMarket
-636000
us-gaap Net Income Loss
NetIncomeLoss
-13711000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
52127000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
60072000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
757000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Mark To Market
AdjustmentsToAdditionalPaidInCapitalMarkToMarket
-14000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-8688000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
52127000
us-gaap Profit Loss
ProfitLoss
-26844000
us-gaap Profit Loss
ProfitLoss
-13711000
us-gaap Depreciation
Depreciation
711000
us-gaap Depreciation
Depreciation
557000
us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
162000
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-77000
us-gaap Share Based Compensation
ShareBasedCompensation
2152000
us-gaap Share Based Compensation
ShareBasedCompensation
1673000
cadl Non Cash Lease Expense
NonCashLeaseExpense
177000
cadl Non Cash Lease Expense
NonCashLeaseExpense
154000
cadl Non Cash Interest Expense
NonCashInterestExpense
77000
cadl Non Cash Interest Expense
NonCashInterestExpense
66000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1449000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-13626000
cadl Accretion Of Debt Discount
AccretionOfDebtDiscount
237000
cadl Accretion Of Debt Discount
AccretionOfDebtDiscount
211000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
230000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-417000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
139000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-127000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-669000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1247000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
830000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-36000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-94000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-343000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-26822000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-24534000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
410000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1021000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
157000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-253000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1021000
us-gaap Proceeds From Bank Debt
ProceedsFromBankDebt
19910000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
28000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
19938000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-27075000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
5617000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
70324000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
83066000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
43249000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
77449000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
156000
us-gaap Interest Paid Net
InterestPaidNet
1592000
us-gaap Interest Paid Net
InterestPaidNet
843000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
2368000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
19000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
261000
cadl Common Stock Exchange For Option Exercise
CommonStockExchangeForOptionExercise
448000
cadl Number Of Product Candidates
NumberOfProductCandidates
2
us-gaap Net Income Loss
NetIncomeLoss
-26800000
us-gaap Net Income Loss
NetIncomeLoss
-13700000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-125900000
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
43000000
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Arial;min-width:fit-content;">preparation of the Company’s condensed </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Arial;min-width:fit-content;">consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and related disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. On an ongoing basis, the Company’s management evaluates its estimates, which include but are not limited to management’s judgments of accrued expenses, valuation of stock-based option awards, valuations of warrants, and income taxes. Actual results could differ from those estimates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Arial;min-width:fit-content;"> </span></p>
cadl Cash And Cash Equivalent Maturity Period
CashAndCashEquivalentMaturityPeriod
P90D
CY2023Q3 us-gaap Restricted Cash
RestrictedCash
300000
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
300000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29042418
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29042418
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
28919810
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
28919810
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Arial;min-width:fit-content;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Periodically, the Company maintains deposits in accredited financial institutions in-excess of the federally insured limits. The Company deposits its cash in financial institutions with a high credit quality and has not experienced any losses on such accounts and does not believe it is exposed to any unusual credit risk beyond the normal risk associated with commercial banking relationships.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Arial;min-width:fit-content;"> </span></p>
CY2023Q3 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
200000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
cadl Expected Dividend Assumed
ExpectedDividendAssumed
0
cadl Percentage Income Taxes Benefits Upon Ultimate Settlement
PercentageIncomeTaxesBenefitsUponUltimateSettlement
0.50
CY2023Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5516000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5553000
CY2023Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1840000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1129000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3676000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4424000
CY2023Q3 us-gaap Depreciation
Depreciation
200000
us-gaap Depreciation
Depreciation
700000
CY2022Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
200000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
600000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
613000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
415000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1774000
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
167000
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1938000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2647000
CY2023Q3 cadl Accrued Third Party Research And Development Expenses Current
AccruedThirdPartyResearchAndDevelopmentExpensesCurrent
1094000
CY2022Q4 cadl Accrued Third Party Research And Development Expenses Current
AccruedThirdPartyResearchAndDevelopmentExpensesCurrent
1486000
CY2023Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
397000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
590000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3429000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4723000
CY2022Q4 us-gaap Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
5000000
CY2022Q4 cadl Cash Proceeds Amount Equal To At Least From The Issuance And Sale Of Equity Securities
CashProceedsAmountEqualToAtLeastFromTheIssuanceAndSaleOfEquitySecurities
75000000
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
0
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
8870000
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
10232000
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
898000
CY2023Q3 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
20000000
CY2023Q3 cadl Debt Instrument Final Payment Fee
DebtInstrumentFinalPaymentFee
900000
CY2023Q3 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
989000
CY2023Q3 cadl Debt Instrument Accretion Of Debt Discount
DebtInstrumentAccretionOfDebtDiscount
528000
CY2023Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
20439000
CY2023Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
6100000
CY2023Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
14339000
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
1607000
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
90000
us-gaap Operating Lease Cost
OperatingLeaseCost
300000
CY2023Q3 us-gaap Variable Lease Cost
VariableLeaseCost
35000
us-gaap Variable Lease Cost
VariableLeaseCost
100000
CY2023Q3 us-gaap Lease Cost
LeaseCost
100000
us-gaap Lease Cost
LeaseCost
400000
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
90000
us-gaap Operating Lease Cost
OperatingLeaseCost
300000
CY2022Q3 us-gaap Variable Lease Cost
VariableLeaseCost
31000
us-gaap Variable Lease Cost
VariableLeaseCost
100000
CY2022Q3 us-gaap Lease Cost
LeaseCost
100000
us-gaap Lease Cost
LeaseCost
400000
CY2023Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
100000
CY2022Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
100000
us-gaap Operating Lease Payments
OperatingLeasePayments
400000
us-gaap Operating Lease Payments
OperatingLeasePayments
400000
us-gaap Operating Lease Payments
OperatingLeasePayments
434000
us-gaap Operating Lease Payments
OperatingLeasePayments
423000
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y10M24D
CY2022Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y10M24D
CY2023Q3 cadl Weighted Average Incremental Borrowing Rate
WeightedAverageIncrementalBorrowingRate
0.0702
CY2022Q3 cadl Weighted Average Incremental Borrowing Rate
WeightedAverageIncrementalBorrowingRate
0.0702
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
148000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
598000
CY2023Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
16144365
CY2022Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
15077409
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
1962770
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5645420
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.77
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1289203
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.3
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
873102
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
2.58
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6061521
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.49
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y2M23D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3478354
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.46
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y29D
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
2583167
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
2.53
cadl Sharebased Compensation Arrangement By Sharebased Payment Award Option Unvested Weighted Average Remaining Contractual
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionUnvestedWeightedAverageRemainingContractual
P8Y9M10D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
0
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
1000000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
686000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
743000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2152000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1673000
CY2023Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
5500000
CY2022Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
7900000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y6M25D
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y4M9D
cadl Noncancelable Operating Lease Expiration Date
NoncancelableOperatingLeaseExpirationDate
2026
us-gaap Loss Contingency Loss In Period
LossContingencyLossInPeriod
0
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-8435000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-8688000
us-gaap Net Income Loss
NetIncomeLoss
-26844000
us-gaap Net Income Loss
NetIncomeLoss
-13711000
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28919810
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28919810
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28891909
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28891909
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28919810
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28919810
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28798284
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28798284
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.29
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.29
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.3
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.3
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.93
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.93
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.48
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.48
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14181595
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13698213

Files In Submission

Name View Source Status
0000950170-23-061566-index-headers.html Edgar Link pending
0000950170-23-061566-index.html Edgar Link pending
0000950170-23-061566.txt Edgar Link pending
0000950170-23-061566-xbrl.zip Edgar Link pending
cadl-20230930.htm Edgar Link pending
cadl-20230930.xsd Edgar Link pending
cadl-ex31_1.htm Edgar Link pending
cadl-ex31_2.htm Edgar Link pending
cadl-ex32_1.htm Edgar Link pending
cadl-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
cadl-20230930_pre.xml Edgar Link unprocessable
cadl-20230930_cal.xml Edgar Link unprocessable
cadl-20230930_lab.xml Edgar Link unprocessable
cadl-20230930_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
cadl-20230930_htm.xml Edgar Link completed
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending